Vanguard Global Advisers’s CareDx CDNA Stock Holding History

Vanguard Global Advisers’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$564K	Hold	19,781	–	–	﹤0.01%	2045
2026 Q1	$343K	Buy	+19,781	New	+$374K	﹤0.01%	2198

Other funds holding CDNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $38.8B AUM 41.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's CDNA Position: Q2 2026 in Review

Vanguard Global Advisers held its CareDx (CDNA) position steady in Q2 2026 at 19,781 shares worth $564K. The position accounts for ﹤0.01% of the portfolio, ranked #2045.

Vanguard Global Advisers first reported a position in CDNA in Q1 2026 and has held it in 2 quarters since. 225 funds tracked by Wall St. Rank hold CDNA as of Q2 2026.

Vanguard Global Advisers held 19,781 shares of CareDx worth $564K as of Q2 2026.
Vanguard Global Advisers left its CareDx share count unchanged in Q2 2026.
CareDx made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2045 holding.
Vanguard Global Advisers first reported a position in CareDx in Q1 2026 and has held it in 2 quarters since.
225 funds tracked by Wall St. Rank held CareDx as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.